Clinical Trial VICCBRE1287


A Phase Ib/II Trial of GDC-0941 (a PI3K inhibitor) in combination with Cisplatin in patients with androgen receptor negative Triple Negative Metastatic Breast Cancer

Principal Investigator(s)

Vandana Abramson


  • Protocol No. VICCBRE1287
  • Open Date: 09/23/2013
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: Local
  • Objective: Ph Ib: To assess the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR-TN MBC. Ph II: To evaluate the efficacy, as measured by the overall response rate (ORR), of cisplatin +GDC-0941 versus cisplatin alone in patients with AR- TN MBC.
  • Disease Sites: Breast
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cisplatin; GDC-0941
  • Participating Institutions: Vanderbilt University; BAPT-Family Cancer Center (MEMPHIS); BAPT-Family Cancer Center (OXFORD); BAPT-Family Cancer Center (BARTLETT); BAPT-Boston Baskin (SOUTHHAVEN)
  • National Clinical Trial ID: NCT01918306
  • Secondary Protocol No: GO28743



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.